| Cash Flow | 2025-10-31 |
|---|---|
| Net loss for the period | -8,278,328 |
| Amortization | 3,818 |
| Financial expenses, net | 89,487 |
| Depreciation | 22,839 |
| Share-based compensation | 294,686 |
| Equity losses | -44,830 |
| Change in fair value of the warrant liability | 69,201 |
| Decrease in amounts receivable and prepaid expenses | 887,860 |
| Decrease in accounts payable | -1,154,788 |
| Increase in accrued expenses and other payables | 494,573 |
| Total cash flow from operating activities | -7,704,796 |
| Equity investment in bc therapeutics | 75,000 |
| Total cash flow from investing activities | -75,000 |
| Increase (decrease) in cash and cash equivalents | -7,779,796 |
| Cash and cash equivalents at beginning of period | 10,493,808 |
| Cash and cash equivalents at end of period | 2,714,012 |
BriaCell Therapeutics Corp. (BCTXW)
BriaCell Therapeutics Corp. (BCTXW)